Export

EN
FR
Emtricitabine + tenofovir
Essential medicine status
Section:
6. Anti-infective medicines 6.4. Antiviral medicines 6.4.2. Antiretrovirals 6.4.2.5. Fixed-dose combinations of antiretrovirals
ATC codes: J05AR03
Indication
Contact with or exposure to human immunodeficiency virus ICD11 code: QC90.6
INN
Emtricitabine + tenofovir
Medicine type
Chemical agent
List type
Core
Formulations
Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
EML status history
First added in 2017 (TRS 1006)
Changed in 2021 (TRS 1035)
Sex
All
Age
Adolescents and adults
Therapeutic alternatives
lamivudine + tenofovir (ATC codes: J05AR12)
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
Emtricitabine + tenofovir
DrugBank
Emtricitabine ,
Tenofovir (Tenofovir disoproxil)
Summary of evidence and Expert Committee recommendations
Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified a as therapeutic alternative for the emtricitabine component under the square box listing for emtricitabine + tenofovir on the EML.